Edition:
United Kingdom

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

10.46USD
16 Aug 2019
Change (% chg)

$0.19 (+1.85%)
Prev Close
$10.27
Open
$10.34
Day's High
$10.69
Day's Low
$10.30
Volume
26,026
Avg. Vol
61,568
52-wk High
$17.80
52-wk Low
$9.23

Becker, Marc 

Mr. Marc Becker is the Chief Financial Officer of Concert Pharmaceuticals Inc, effective on January 4, 2018. Mr. Becker served as the Chief Financial Officer of CRISPR Therapeutics AG, a publicly traded biotechnology company, from February 2016 to September 2017. From January 2012 to February 2016, Mr. Becker was the Chief Financial Officer of rEVO Biologics, Inc., a biotechnology company. Prior to rEVO Biologics, Mr. Becker held roles of increasing responsibility at Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A., from August 2001 to October 2011, culminating in Vice President, Finance. Mr. Becker received an M.B.A. from Babson College and a B.S. in Business Administration from the University of Massachusetts and was licensed as a certified public accountant.

Basic Compensation

Total Annual Compensation, USD 405,682
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,044,850
Fiscal Year Total, USD 2,450,530

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

205,613

Roger Tung

4,607,850

Marc Becker

2,450,530

Nancy Stuart

1,908,030

James Cassella

1,960,240

Thomas Auchincloss

205,613
As Of  31 Dec 2018